Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4988573 | 0.79 | CYP11B2 (0.36) | CYP11B2KDM4AKDM5AKDM4CKDM5B | |
| SCHEMBL3494477 | 0.77 | USP30 (0.39) | — | |
| SCHEMBL3496018 | 0.73 | CYP11B2 (0.35) | CYP11B2KDM4AKDM5AKDM4CKDM5B | |
| SCHEMBL3491411 | 0.73 | CYP11B2 (0.49) | CYP11B2KDM4AKDM5AKDM4CKDM5B | |
| SCHEMBL3495602 | 0.72 | CYP11B2 (0.34) | CYP11B2 | |
| SCHEMBL3493920 | 0.72 | CYP11B2 (0.34) | CYP11B2 | |
| SCHEMBL3493922 | 0.72 | CYP11B2 (0.34) | CYP11B2 | |
| SCHEMBL13341052 | 0.71 | EGFR (0.39) | — | |
| SCHEMBL3494782 | 0.70 | CYP11B2 (0.44) | CYP11B2 | |
| SCHEMBL3495160 | 0.70 | CYP11B2 (0.34) | CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | CYP11B2 29/4885KDM4A 1218/4885KDM5A 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.